Moderna（MRNA）今日盘中大幅上涨5.03%，报57.23美元/股，成交额达1.41亿美元，引发市场广泛关注。
消息面上，多重利好因素共同推动了此次股价上涨。公司即将发布第二季度财报，市场对其业绩表现抱有较高期待。近期多家华尔街机构密集上调Moderna目标价：高盛将目标价从49美元大幅上调至67美元，维持中性评级；杰富瑞上调至60美元；Piper Sandler则上调至77美元并维持增持评级。此外，公司季节性流感疫苗候选产品mRNA-1010获得FDA咨询委员会9票赞成、0票反对的一致支持，最终审批结果即将公布。管线方面，公司肿瘤靶向癌症抗原疗法一期临床已完成首例患者给药，多元化布局持续推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.